Aminopterin
- Generic Name
- Aminopterin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N8O5
- CAS Number
- 54-62-6
- Unique Ingredient Identifier
- JYB41CTM2Q
- Background
Aminopterin is an amino derivative of folic acid, which was once used as an antineoplastic agent in the treatment of pediatric leukemia. In the 1950's its production was discontinued in favor of methotrexate, which is less potent but less toxic. Off label, aminopterin has also been used in the treatment of psoriasis. Clinicians need to be aware of the charac...
- Indication
Prior to its withdrawal, aminopterin was initially used in the treatment of childhood leukemia; specifically to induce remissions. Later, aminopterin was used off-label in the United States to treat psoriasis, yielding dramatic lesion clearing. Aminopterin was later supplanted by methotrexate for treating cancer because of its better therapeutic index. Amino...
- Associated Conditions
- -
- Associated Therapies
- -
Aminopterin Pharmacokinetic Study In Moderate to Severe Psoriasis
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2019-09-20
- Lead Sponsor
- Syntrix Biosystems, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT00937027
- Locations
- 🇺🇸
Baylor Research Institute, Dallas, Texas, United States
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Rutgers, The State University of New Jersey
- Target Recruit Count
- 60
- Registration Number
- NCT00176462
- Locations
- 🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer
- Conditions
- First Posted Date
- 2004-08-04
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Genzyme, a Sanofi Company
- Registration Number
- NCT00003821
- Locations
- 🇺🇸
University of Wisconsin Comprehensive Cancer Center, Madison, Wisconsin, United States
🇺🇸Gynecologic Oncologists of NE Ohio, Akron, Ohio, United States
🇺🇸Simmons Cancer Center - Dallas, Dallas, Texas, United States
Aminopterin in Treating Patients With Refractory Leukemia
- Conditions
- First Posted Date
- 2004-08-02
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 75
- Registration Number
- NCT00003305
- Locations
- 🇺🇸
Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Urology San Antonio Research, San Antonio, Texas, United States
🇺🇸Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.